secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001683168-24-000985
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical Q3 net loss widens to $3.6M; expenses up 25% on CEO separation costs
--------------------------------------------------------------------------------

- Net loss of $3.6M for fiscal Q3 ended Dec 31, 2023, vs $2.8M a year ago.
- Operating expenses $3.6M (+25% YoY), driven by $873K in former CEO separation costs.
- Cash balance $8.0M as of Dec 31, 2023; company focusing on expense reduction.
- Received DCGI clearance in India for phase 1 trial of Hemopurifier in solid tumors.
- In vitro binding study results inconclusive; engaging third-party labs for independent assays.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316824000985/0001683168-24-000985-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316824000985/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-000985

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer